Abbott’s investigational interferon-free Hepatitis C treatment regimen achieved SVR12 (observed data) rates in 99 percent of treatment-naïve
15 October 2012 | By Abbott
Initial results from "Aviator"...
List view / Grid view
15 October 2012 | By Abbott
Initial results from "Aviator"...
15 October 2012 | By Merck
Merck and AiCuris enter into an agreement...
14 October 2012 | By Amgen
Data from several Prolia® studies...
13 October 2012 | By Merck
Odanacatib significantly increased BMD following prior alendronate treatment...
12 October 2012 | By Amgen
Amgen has announced the appointment of Cynthia M. Patton...
12 October 2012 | By Biogen Idec
New data from studies evaluating oral BG-12...
12 October 2012 | By Novartis
Gilenya® the first once-daily oral therapy...
12 October 2012 | By Sanofi
Sanofi and Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the ECTRIMS...
11 October 2012 | By GlaxoSmithKline
Greater openness, transparency and collaboration...
11 October 2012 | By Boehringer Ingelheim
Final guidance issued on the use of alteplase...
11 October 2012 | By Biogen Idec
Results from 11 company-sponsored TYSABRI presentations...
11 October 2012 | By Pfizer
“These top-line data provide evidence of the long-term safety of ALO-02..."
11 October 2012 | By Merck
World Health Organization commends the MECTIZAN® Donation Program on its contribution to near-elimination of river blindness from the Western Hemisphere...
10 October 2012 | By Novartis
New data to be presented...
10 October 2012 | By ANDREW LLOYD & ASSOCIATES
New plant on its Mourenx, France site to produce a large volume commercial API...